WM-A1-3389 + pembrolizumab

WM-A1-3389 + pembrolizumab is an investigational combination therapy for cancer. WM-A1-3389 is a novel therapeutic antibody developed by Wellmarker Bio that targets a newly identified immune checkpoint protein. It has shown preclinical efficacy, particularly in non-small cell lung cancer (NSCLC) models with low or no PD-L1 expression, areas where current PD-1 inhibitors like pembrolizumab (Keytruda, an anti-PD-1 monoclonal antibody marketed by Merck) often have limited effectiveness. The combination aims to produce an additive or synergistic immunotherapeutic effect by pairing WM-A1-3389’s distinct mechanism with pembrolizumab’s established checkpoint blockade, with the goal of improving responses in patient populations with unmet needs. The combination is currently under evaluation in early clinical trials for advanced solid tumors and NSCLC, with planned future expansion to other cancers[1][2][4][5][6][7][9].

Other names

WM-A1-3389 + Keytruda